OncoArendi Therapeutics has signed an exclusive agreement

with one of the top 10 U.S. Universities for the development of inhibitors of new, validated biological targets for the treatment of anti-inflammatory diseases. Further details of this agreement cannot be disclosed at this time.

meatnetadmOncoArendi Therapeutics has signed an exclusive agreement
Czytaj więcej

OncoArendi Therapeutics has closed its angel investment round raising

through emission and acquisition of new shares, a total of 3.5 million PLN (approx. 1.1 million USD). Proceeds from this round will be used to supplement public financing in two ongoing discovery programs and launch a third program for the development of anti-inflammatory drug candidates.

meatnetadmOncoArendi Therapeutics has closed its angel investment round raising
Czytaj więcej

The Nencki Institute of Experimental Biology has just signed

a contract with the National Center for Research and Developemnt for co-financing of a 7 Miliion PLN, 30-month collaborative preclinical research and development project of a propriatary oncology drug candidate – OAT449. OncoArendi Therapeutics will be the sole owner of the research results of this joint project and plans to bring the preclinical work through GLP toxicology to the pre-ind stage. The funding source is Action 1.3.1 of the Innovative Economy Operational Programme.

meatnetadmThe Nencki Institute of Experimental Biology has just signed
Czytaj więcej

A patent application for the OAT-449

drug candidate is simultaneously filed by OncoArendi Therapeutics with the United States Patent and Trademark Office (USPTO) and with the Patent Office of the Republic of Poland.

meatnetadmA patent application for the OAT-449
Czytaj więcej

Funding received for the first discovery program

OncoArendi was successful in securing 1,6M in public financing in an joint application with the Institute of Biophysics and Biochemistry, Polish Academy of Sciences and the International Institute for Molecular and Cell Biology for a project entitled “New drug candidates for targeted therapy of multiple myeloma”.

meatnetadmFunding received for the first discovery program
Czytaj więcej